MDS Clinical Trials in New York, New York

6 studies are recruiting for mds in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML

   This is a Phase 1b open-label, multicenter, dose-escalation and dose-optimization study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor efficacy of eganelisib as monotherapy and in combination with cytarabine in patients with relapsed/refr…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center, New York, New York

   Locations

   13 in total

   Run by

   Stelexis BioSciences

   See if you can join NCT06533761 on ClinicalTrials.gov

2. A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

   This is a multicenter, genetically-randomized, controlled, Phase 3 study evaluating the efficacy and safety of T-cell receptor-engineered donor T cells targeting HA-2 (TSC-101) administered following reduced-intensity conditioning (RIC) hematopoietic cell transplantation (HCT) in participants with …

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Mount Sinai Hospital, New York, New York

   Locations

   26 in total

   Run by

   TScan Therapeutics, Inc.

   See if you can join NCT07702578 on ClinicalTrials.gov

3. A Phase 1/3 Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

   This is a multi-center, non-randomized, concurrent controlled, multi-arm, Phase 1 interventional, open-label, biologic assignment-based umbrella study evaluating the feasibility, safety and preliminary efficacy of an escalating dose regimen of up to 2 doses of TSC-100 and TSC-101 in patients with A…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Columbia University, New York, New York

   Locations

   21 in total

   Run by

   TScan Therapeutics, Inc.

   See if you can join NCT05473910 on ClinicalTrials.gov

4. Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders

   This is a single-arm study to investigate 1-year treatment related mortality (TRM) in patients with life threatening non-malignant and malignant hematologic disorders who do not have a matched related donor for allogeneic transplantation.

   Stage

   Phase 2

   Ages

   Up to 21

   Site

   Memorial Sloan Kettering Cancer Center, New York, New York

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT04644016 on ClinicalTrials.gov

5. A Long Term Follow-up Study of TScan TCR-T Products

   The purpose of this Long-Term Follow-Up (LTFU) study is to monitor participants who have previously received TSC-100 or TSC-101 TCR-T therapies in the TSCAN-001 study. Participants will be monitored for 15 years from the date of TCR-T cell therapy administration to assess long-term safety and effic…

   Stage

   Not phased

   Ages

   18 to 110

   Site

   Mount Sinai, New York, New York

   Locations

   2 in total

   Run by

   TScan Therapeutics, Inc.

   See if you can join NCT06976736 on ClinicalTrials.gov

6. Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

   Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This trial aims to examine the safety of this novel agent in pediatric patie…

   Stage

   Phase 1

   Ages

   1 to 21

   Site

   Memorial Sloan Kettering Cancer Center, New York, New York

   Locations

   31 in total

   Run by

   Therapeutic Advances in Childhood Leukemia Consortium

   See if you can join NCT05476770 on ClinicalTrials.gov